How this risk actually develops
Acute kidney injury (AKI) associated with GLP-1 medications is generally not a direct effect of the drug on the kidneys — it's typically the downstream consequence of a chain starting with unmanaged GI side effects. A 2025 case report illustrates this pathway clearly: a patient who resumed semaglutide at a high dose without following the recommended gradual titration schedule developed severe nausea and vomiting, which led to dehydration and, from there, acute kidney injury (Singhal et al., Cureus, 2025, DOI (external link)). Notably, the same 2025 meta-analysis of GLP-1 trials found GLP-1s were actually associated with a reduction in acute kidney failure overall (-9%) compared with placebo (Galli et al., JACC, 2025, DOI (external link)) — reinforcing that the risk is specifically tied to unmanaged dehydration from GI symptoms or improper titration, not an inherent property of the medication itself.
The chain worth understanding
- Rapid dose escalation or an unusually strong individual response leads to significant nausea and/or vomiting
- Vomiting and reduced fluid intake (often alongside reduced food intake from appetite suppression) lead to dehydration
- Dehydration, if significant and prolonged, can reduce blood flow to the kidneys enough to cause injury
Each link in this chain is interruptible — which is the practical takeaway.